POTENTIAL INTERACTIONS BETWEEN CARDIOVASCULAR AND COVID-19 MEDICATION REGIMENS AMONG PATIENTS WITH HEART FAILURE

Since December 2019, the COVID-19 pandemic has led to significant mortality in world. Based on epidemiological data from China, 20% or more of patients had cardiovascular comorbidities. Life-threatening complications due can develop these patients. Meanwhile, risk may be higher with heart failure (HF), who usually have older people and lead myocardial injury disease exacerbation HF a cytokine storm-related hyper-inflammation syndrome.1 Hence, most studies only addressed prevalence among less specifically HF. A study China found that 23% HF, which 52% died.2 On other hand, it been suggested cause damage specific condition characteristics this syndrome.3 Therefore, is important pay attention consequences COVID-19. Despite, effect different drug therapies outcomes management potential interactions between medication regimens remains an challenging clinical issue. In early pandemic, antiviral drugs such as hydroxychloroquine were widely used manage infection. Chloroquine are potassium channel blockers prolong QTc play role sudden cardiac death. This process becomes especially dangerous when combined treatments, including prolonging azithromycin lopinavir/ritonavir. at particular for addition, advanced treatments patients, occur regimen. For example, left ventricular assist devices (LVAD) treated anticoagulation warfarin. Warfarin vitamin k antagonist interact some treatment COVID-19.4 Previous evidences shown chloroquine digoxin antiarrhythmic associated possibility QT prolongation, arrhythmias.5,6 Remdesivir, made treat Ebola, little against SARS-CoV-2. Despite lack interaction Remdesivir drugs, receiving closely monitored prolongation electrolyte disturbances. 1 sum, previous evidence regarding limited no strong available. further needed identify interactions. Given increasing incidence essential better understand SARS-CoV-2 order Also, multidisciplinary approach members team pandemic. References Zhang Y, Coats AJ, Zheng Z, Adamo M, Ambrosio G, Anker SD, et al. Management COVID‐19: joint position paper Chinese Heart Failure Association & National Committee European Society Cardiology. Eur J Fail. 2020;22(6):941-56. Zhou F, Yu T, Du R, Fan Liu Clinical course factors adult inpatients Wuhan, China: retrospective cohort study. Lancet. 2020;395(10229):1054-62. Madjid Safavi-Naeini P, Solomon Vardeny O. Potential effects coronaviruses system: review. JAMA Cardiol. 2020;5(7):831-40. Bader Manla Atallah B, Starling RC. Fail Rev. 2021;26(1):1-10. Chorin E, Wadhwani L, Magnani S, Dai Shulman Nadeau-Routhier C, interval torsade de pointes hydroxychloroquine/azithromycin. Rhythm. 2020;17(9):1425-33. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Risk use without concomitant hospitalized testing positive coronavirus 2019 (COVID-19). 2020;5(9):1036-41.